Verition Fund Management
ATXS

Verition Fund Management’s Astria Therapeutics ATXS Stock Holding History

Verition Fund Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,918
Closed -$208K – 3239
2024
Q3 		$208K Sell
18,918
-369
-2% -$4.1K ﹤0.01% 2866
2024
Q2 		$176K Buy
+19,287
New +$188K ﹤0.01% 2635
2023
Q2 		– Sell
-16,794
Closed -$223K – 2201
2023
Q1 		$223K Buy
+16,794
New +$227K ﹤0.01% 1703

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Verition Fund Management's ATXS Position: Q4 2024 in Review

Verition Fund Management sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 18,918 shares — an estimated $208K sold.

Verition Fund Management first reported a position in ATXS in Q1 2023 and held it in 3 quarters. The position peaked at $223K in Q1 2023. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

  • Verition Fund Management reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Verition Fund Management sold 18,918 Astria Therapeutics shares in Q4 2024, an estimated $208K.
  • Verition Fund Management first reported a position in Astria Therapeutics in Q1 2023 and held it in 3 quarters.
  • Verition Fund Management's Astria Therapeutics position peaked at $223K in Q1 2023.
  • 110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on Verition Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.